714 results on '"Little, Richard F."'
Search Results
2. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
3. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool
4. Critical Components of Clinical Trials Development: From Bench to Bedside and Back
5. The NCI-MATCH trial: lessons for precision oncology
6. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
7. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
8. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
9. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
10. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
11. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
12. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
13. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
14. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
15. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases
16. Human Immunodeficiency Virus-Related Lymphomas
17. Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial
18. Presentation and Pathogenesis of B-Cell Lymphoid Cancers Associated with HIV Infection
19. Viral, immunologic, and clinical features of primary effusion lymphoma
20. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
21. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
22. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
23. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
24. The New NCI Precision Medicine Trials
25. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)
26. Integral Components in Development of Clinical Trials: PK/PD, Statistics, and Principles of Rational Combinatorial Therapies
27. Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials
28. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
29. Human Immunodeficiency Virus-Related Lymphomas
30. Supplementary Figure Legends from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
31. Supplementary Table S2: Clinical trials in myeloma using MRD assessments from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
32. Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
33. Supplementary Figure S1 from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
34. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials
35. An Agenda to Advance Research in Myelodysplastic Syndromes: A TOP 10 Priority List From the First International Workshop in MDS
36. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial
37. Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS)
38. Presentation and Pathogenesis of B-Cell Lymphoid Cancers Associated with HIV Infection
39. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus
40. A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
41. Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
42. Update on Enrollment of Older Adults Onto National Cancer Institute National Clinical Trials Network Trials
43. Integrating Geriatric Assessment Measures into National Cancer Institute Clinical Trials
44. Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
45. A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
46. How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform
47. ¹⁸F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters
48. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease
49. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS)
50. Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.